Edgar Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Edgar Gonzalez has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Evanthia T. Roussos Torres
University of Southern California
35 shared publications - Aaron G. Baugh
University of Southern California 1 Division of Oncology, Department of Medicine, Keck School of Medicine Los Angeles, California
33 shared publications - Roisin M. Connolly
Cancer Research @UCC, College of Medicine and Health, University College Cork, Cork, Ireland
33 shared publications - Vered Stearns
Department of Medicine, Weill Cornell Medicine, New York, NY
33 shared publications - Adam L. MacLean
University of Southern California
21 shared publications - Amanda Poissonnier
Oregon Health & Science University 5 Knight Cancer Institute Portland, Oregon
20 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can sensitize tumors to dual checkpoint inhibition in patients. Here, we investigated the tumor microenvironment (TME) of breast metastases by combining experimental and clinical data with theory to elucidate the mechanism of response to treatment with the HDAC inhibitor entinostat combined with anti–PD-1 and anti–CTLA-4. Knowledge-guided subclustering of single-cell RNA-sequencing (scRNA-seq) data and cell circuit analyses from murine breast-to-lung metastases identified 39 cell states and salient interactions, of which myeloid, T-cell, and B-cell subpopulations were most affected. Analyses of patient biopsy specimens and blood via spatial proteomics and flow cytometry corroborated the preclinical findings, showing increased T- and B-cell activation, mature tertiary lymphoid structures, and increased CD8+ T cell–macrophage distances in responders to entinostat + nivolumab + ipilimumab. Combination treatment increased immunoglobulin production in patients and mice, and murine studies demonstrated increased tumor-targeting IgG and implicated B cells as necessary for treatment response. Inhibition of the intercellular adhesion molecule 1 and IFNγ pathways in myeloid cells partially recapitulated treatment effects on CD8+ T cells observed via scRNA-seq. Mathematical modeling of tumor-immune dynamics implicated simultaneous modulation of multiple TME interactions as required for response to the combination treatment. Overall, this study identifies lymphoid and myeloid cell contributions to response to treatment with HDAC inhibitors and immune checkpoint blockade, providing a framework for discovering interactions driving responses in complex TMEs. Significance:Integrative data analysis and mathematical modeling reveal immune interactions that sensitize the metastatic tumor microenvironment to checkpoint inhibition, validating the potential of cancer systems immunology approaches to uncover mechanisms of immunotherapeutic response.See related commentary by Senent and Manguso, p. 5603
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can sensitize tumors to dual checkpoint inhibition in patients. Here, we investigated the tumor microenvironment (TME) of breast metastases by combining experimental and clinical data with theory to elucidate the mechanism of response to treatment with the HDAC inhibitor entinostat combined with anti–PD-1 and anti–CTLA-4. Knowledge-guided subclustering of single-cell RNA-sequencing (scRNA-seq) data and cell circuit analyses from murine breast-to-lung metastases identified 39 cell states and salient interactions, of which myeloid, T-cell, and B-cell subpopulations were most affected. Analyses of patient biopsy specimens and blood via spatial proteomics and flow cytometry corroborated the preclinical findings, showing increased T- and B-cell activation, mature tertiary lymphoid structures, and increased CD8+ T cell–macrophage distances in responders to entinostat + nivolumab + ipilimumab. Combination treatment increased immunoglobulin production in patients and mice, and murine studies demonstrated increased tumor-targeting IgG and implicated B cells as necessary for treatment response. Inhibition of the intercellular adhesion molecule 1 and IFNγ pathways in myeloid cells partially recapitulated treatment effects on CD8+ T cells observed via scRNA-seq. Mathematical modeling of tumor-immune dynamics implicated simultaneous modulation of multiple TME interactions as required for response to the combination treatment. Overall, this study identifies lymphoid and myeloid cell contributions to response to treatment with HDAC inhibitors and immune checkpoint blockade, providing a framework for discovering interactions driving responses in complex TMEs. Significance:Integrative data analysis and mathematical modeling reveal immune interactions that sensitize the metastatic tumor microenvironment to checkpoint inhibition, validating the potential of cancer systems immunology approaches to uncover mechanisms of immunotherapeutic response.See related commentary by Senent and Manguso, p. 5603
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Expression of fibroblast markers in NT2.5 mammary tumors and NT2.5-LM lung metastases.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Expression of fibroblast markers in NT2.5 mammary tumors and NT2.5-LM lung metastases.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S11 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
CC-model cell circuit analysis.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S11 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
CC-model cell circuit analysis.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S12 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analyses of CD8+ T cell co-cultures with myeloid cells from NT2.5-LM or 4T1 lung metastases.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S12 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analyses of CD8+ T cell co-cultures with myeloid cells from NT2.5-LM or 4T1 lung metastases.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
CC-suppression cell circuit analysis.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
CC-suppression cell circuit analysis.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S13 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Differences in immune cell proportions and expression of functional markers associated with treatments in patient IMC data.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S13 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Differences in immune cell proportions and expression of functional markers associated with treatments in patient IMC data.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of mature myeloid cells in NT2.5-LM lung metastases with treatments.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of mature myeloid cells in NT2.5-LM lung metastases with treatments.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of T cells in NT2.5-LM lung metastases with treatments.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of T cells in NT2.5-LM lung metastases with treatments.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Determination of mature myeloid and T cell proportions with treatments in 4T1 lung metastases via conventional flow cytometry.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Determination of mature myeloid and T cell proportions with treatments in 4T1 lung metastases via conventional flow cytometry.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of MDSC and NK cell populations in NT2.5-LM lung metastases with treatments.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer
Analysis of MDSC and NK cell populations in NT2.5-LM lung metastases with treatments.